TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the completion of enrollment in two, phase 2 clinical studies of PRO 140, an investigational drug that is being developed for treatment of human immunodeficiency virus (HIV) infection. The phase 2 studies are separately evaluating intravenous and subcutaneous forms of PRO 140. The Company also reported that interim antiviral and tolerability data from the phase 2 study of intravenous PRO 140 have been selected for presentation in a “late-breaker” session at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) to be held October 25-28, 2008 in Washington, D.C. Finally, the Company announced the online publication of results from a phase 1b study, authored by Progenics’ scientists and their academic collaborators, of intravenous PRO 140 in the Journal of Infectious Diseases, a peer-reviewed science journal.
